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Many drugs have been reported to induce lupus in a minority of patients. Ticlopidine hydrochloride
inhibits platelet aggregation and is widely used for the prevention of thrombosis. There have been only a
few reports of ticlopidine-induced lupus. Here, we review 13 previously reported cases and describe the
case of a 71-year-old man with ticlopidine-induced subacute cutaneous lupus erythematosus. His
diagnosis was supported by the appearance of papulosquamous skin lesions on sun-exposed areas and
detectable anti-Ro/SS-A antibodies, shortly after drug initiation as well as the gradual resolution of these
symptoms after the discontinuation of ticlopidine. Our case highlights that when a patient presents with
subacute cutaneous lupus erythematosus-like skin lesions, ticlopidine should be considered as a po-
tential causative agent.
Copyright  2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Since the report of skin reactions to hydrochlorothiazide in
conjunction with Ro⁄SS-A autoantibody after the drug was ﬁrst
introduced in 1985,1 more than 40 types of drugs have been re-
ported to induce subacute cutaneous lupus erythematosus
(SCLE).2e4 Ticlopidine hydrochloride is a platelet aggregation in-
hibitor used as a substitute for aspirin in patients who cannot
tolerate the side effects of aspirin.5 It is commonly prescribed for
stroke prevention6 or after coronary artery stenting to prevent
thrombosis based on Food and Drug Administration-labeled in-
dications. Common adverse drug reactions of ticlopidine are diar-
rhea, exanthematus eruptions, and rarely neutropenia or bone
marrow aplasia.7 Ticlopidine-induced SCLE is extremely rare. Here,
we describe the case of a patient with ticlopidine-induced SCLE
who was diagnosed based on his clinical medication history, and
the clinical, histological, and immunopathological results.y have no ﬁnancial or non-
tter or materials discussed in
y, Mackay Memorial Hospital,
iwanese Dermatological AssociatioCase report
A 71-year-old man suffered from multiple skin rashes on his trunk
and limbs for 2 months. The rashes did not respond to topical
steroid treatment. On physical examination, many scaly reddish
papules and plaques were observed on the scalp, face, forearms,
upper chest, and upper back (Figure 1AeC). He showed no sign of
fever, arthralgia, myalgia, pleurisy, or pericarditis. The distribution
of the skin rashwas mainly on sun-exposed areas, and thus, SCLE or
photosensitive lichenoid drug eruptionwas considered. Blood tests,
urine tests, and incisional biopsy for pathology and immunoﬂuo-
rescence were performed.
Based on the medical and medication history, he had suffered
from essential hypertension, benign prostate hyperplasia, and type
2 diabetesmellitus formany years. Hewas persistently treatedwith
losartan, isosorbide dinitrate, propranolol, tamsulosin, desmo-
pressin, bromazepam, acarbose, glimepiride, and sitagliptin
without change for more than 1 year. He was diagnosed with car-
diovascular disease after coronary artery stenting that occurred 2
years prior to admission. Subsequently, he had taken aspirin for
thrombus prevention until 4 months ago when he was prescribed
ticlopidine hydrochloride as an aspirin substitute due to gastroin-
testinal discomfort.
The blood test results revealed anemia (hemoglobin: 9.8 mg/dL)
and the urine test results suggested proteinuria. The other test
items, including liver and renal functions, were within the normaln. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Multiple scaly erythematous plaques on the (A) upper chest and (B) upper back. (C) A close view of the reddish papulosquamous papuloplaques on the extensor side of the
right forearm.
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(antinuclear factor 40X; speckled/centromere) and identiﬁed as
anti-Ro antibodies (anti-Ro 347 AU/mL; normal range: <120 AU/
mL). Other tests to survey for connective tissue disease werewithin
normal limits, including C3, C4, and anti-double-stranded DNA.
Histological examination revealed diffuse vacuolar degenera-
tion of the basal layers of keratinocytes (Figure 2A and B) and mild
to moderate lymphocytic perivascular inﬁltrates in the upper
dermis. There was focal parakeratosis and lymphocytic exocytosis
in the epidermis, but neither an increase in dermal mucin deposi-
tion nor basement membrane thickening was observed. Eosino-
phils were rare. Direct immunoﬂuorescent tests of the involved
skin showed deposition of cytoid bodies that expressed immuno-
globulins (Ig), including IgA, IgG, and IgM (Figure 2C and D). There
was also ﬁbrinogen deposition along the dermaleepidermal junc-
tion. The overall features represented interface dermatitis andwere
consistent with a connective tissue disorder such as lupus erythe-
matosus or dermatomyositis.
Dermatomyositis was less likely because of the absence of
muscle weakness and normal blood tests for muscle enzymes. The
diagnosis after clinicopathological correlation was SCLE. The pres-
ence of anti-Ro antibody and his medication history raised thepossibility of drug-induced SCLE. Ticlopidine hydrochloride, the
only recent addition to the medical regimen, was highly suspected.
He was asked to discontinue oral ticlopidine, and a topical potent
steroid (0.05% ﬂuocinonide) was prescribed without oral medica-
tion. After discontinuation of ticlopidine, the skin lesions rapidly
improved and completely subsided 4 weeks later. Therefore, no
further blood test was performed. Lesions did not recur during the
1-year follow-up period.
Discussion
There have been only 12 cases of ticlopidine-induced lupus and
only two cases of ticlopidine-induced SCLE reported in the litera-
ture (Table 1).8,15e20 The time from ticlopidine exposure to the
onset of drug-induced lupus varied from 1 week to 4 years. Most
patients started to feel better after discontinuing ticlopidine for
several weeks and completely recovered after several months.
ANAs and antihistone antibodies are a common ﬁnding in drug-
induced lupus and are detected in almost all ticlopidine-induced
systemic lupus cases. ANAs and Ro/SS-A autoantibodies were
detected in both cases of ticlopidine-induced SCLE. The case of
ticlopidine-induced SCLE reported in Poland8 shares many similar
Figure 2 (A) Histopathological analysis (scanning magniﬁcation) showed moderate superﬁcial and deep perivascular inﬁltrates. (B) High-powered images demonstrated diffuse
vacuolar degeneration of the basal keratinocytes [hematoxylin and eosin: (A) 100; (B) 400]. (C) Many immunoglobulin G (IgG)-deposited ovoid bodies were present at the
dermaleepidermal junction and papillary dermis. (D) Scattered IgM-deposited ovoid bodies at the dermaleepidermal junction [direct immunoﬂuorescence test: (C) 400, (D)
400].
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presence of anti-Ro/SS-A autoantibodies, interface dermatitis, and
the resolution of cutaneous lesions soon after discontinuing
ticlopidine.
There is no signiﬁcant difference between drug-induced and
non-drug-induced SCLE based on clinical, histopathological, or
immunopathological features.9,10 Both present with annular/Table 1 Summary of previous reports and present case on ticlopidine-induced lupus ery
Ref. Age (y) Sex Presentation Immunologica
Japan15 81 M Fever, arthralgia,
myalgia, pericardial effusion
ANA (1:640), a
76 M Fever, pleural effusion,
myalgia
ANA (1:2560)
Japan16 71 M Fever, arthralgia, pleural
effusion þ mesangial
proliferative glomerulonephritis
ANA (1:640), a
anti-dsDNA, a
Japan17 55 M Fever, arthralgia, under
hemodialysis
ANA, antihisto
anti-dsDNA
Japan18 62 M Arthralgia, pleuritis ANA
USA19 74 M Fever, polyarthritis, myalgia ANA, antihisto
76 F Polyarthritis, myalgia ANA, antihisto
anti-dsDNA
73 F Serositis, arthritis ANA, antihisto
anti-dsDNA, a
67 F Pleurisy, polyarthritis ANA, antihisto
anti-dsDNA
Israel20 77 M Polyarthritis, urticaria ANA, antihisto
69 F Fever, arthritis, proteinuria ANA, antihisto
anti-dsDNA
53 M Fever, polyarthritis ANA, antihisto
Poland8 76 F Annular SCLE ANA, anti-Ro
Taiwan 71 M Annular SCLE ANA, anti-Ro
ANA ¼ antinuclear antibody; anti-dsDNA ¼ anti-double-stranded DNA; anti-ssDNA
inﬂammatory drug; SCLE ¼ subacute cutaneous lupus erythematosus.papulosquamous lesions occurring mainly in sun-exposed areas,
interface dermatitis with perivascular lymphocytes inﬁltration, and
detectable ANA, anti-Ro/SS-A (a positive result is obtained in more
than 80% of cases2), or occasionally anti-La/SS-B autoantibodies.
Attempting to distinguish drug-induced from non-drug-induced
SCLE by tissue eosinophilia is not reliable or feasible.11 One clue
for a physician to consider is that drug-induced SCLE often affectsthematosus.
l ﬁnding Duration of
exposure
Resolution
time
Treatment
ntihistone 4 y 5 min Prednisolone
30 mg/d þ pulse therapy
, antihistone 1 y 4 min Nil
ntihistone,
nti-ssDNA
2 y 2 min Prednisolone 15 mg/d
ne, 7 mo Weeks Nil
9 mo d Nil
ne 9 mo 2 min Prednisolone 5 mg/d
ne, <1 y 1 min Prednisolone 5 mg/d
ne,
nticardiolipin
4 y 3 min Prednisolone 20 mg/d þ MTX
ne, 1 y 10 min Prednisolone 5e10 mg/d,
hydroxylchloroquine
ne 2 wk 2e3 min NSAID
ne, 2 min 3 min Prednisone 15e30 mg/d
ne 2 wk 4 min Nil
1 wk 4 min Topical potent steroid
4 min 4 wk Topical potent steroid
¼ anti-single-stranded DNA; MTX ¼ methotrexate; NSAID ¼ nonsteroidal anti-
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larly those being treated with antihypertensive or antifungal
agents.2,3,12 Although the golden standard for a deﬁnite diagnosis is
a rechallenge test, it is not ethical in most situations. Therefore, a
diagnosis can also be made if a complete recovery is achieved after
halting the suspected medication.
The pathogenesis underlying drug-induced SCLE is unclear, but
is probably multifactorial and complex.10,13 Reed et al1 proposed
possible mechanisms that included enhancing Ro/SS-A antigen
expression, enhancing epidermal cytotoxicity through direct
phototoxicity, or enhancing anti-Ro/SS-A antibody production. In
the review by Lowe et al3 and the study by Sontheimer et al,4 many
drugs that trigger SCLE were argued to do so by inducing a
photosensitivity state. There has been no report that ticlopidine
could cause a photosensitive reaction but its chemical analog, the
thienopyridine (clopidogrel), has been reported to induce photo-
sensitive lichenoid eruption.14
In conclusion, ticlopidine-induced lupus erythematosus is a rare
entity. Drug-induced SCLE should be considered when elderly pa-
tients present with an SCLE-like skin rash that is conﬁrmed by
histological analysis. Physicians should review the complete
medication history and identify the possible candidate drug.
Discontinuation of the causative drug and sun protection are the
best way to treat patients who have drug-induced LE, rather than
systemic corticosteroid treatment that may result in complications
in these patients.
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